Table 2

Dalbavancin indication, dosage, duration of previous antibiotic, concomitant antibiotic use and its duration, and result

Indicationn (%)Duration of previous antibiotic (days)*Dalbavancin dosageConcomit antantibioticn (%)Duration of concomit antantibiotic (days)*Successn (%)Notincludedn (%)
Initialdose(mg)Subsequent dose(s)Days forsubsequent dose(s)N (%)
Skin and soft tissue infections 31 (30.4)18.5 (13–29.8)150060 (58.8)Moxifloxacin 8 (7.8)
Linezolid 4 (3.9)
Ciprofloxacin2 (2)
Trimethoprim/
sulfamethoxazole 1 (1)
Cefditoren 1 (1)
Cloxacillin 1 (1)
14 (5–28)89 (93.7)7 (6.9)
Catheter-related1×1500 mg1514 (13.7)
Bacteraemia 16 (15.7)2×1500 mg153 (2.9)
Endocarditis6×1500 mg152 (1.9)
14 (13.7)1×1500 mg71 (1)
Bacteraemia with5×1500 mg301 (1)
suspected endocarditis 11 (10.8)151 (1)
Prosthetic joint1×500 mg151 (1)
infection 11 (10.8)1×1000 mg151 (1)
Osteomyelitis2×500 mg71 (1)
11 (10.8)5×500 mg71 (1)
Bacteraemia1000500 mg78 (7.8)
5 (4.9)--3 (2.9)
Septic arthritis5×500 mg72 (1.9)
2 (1.9)2×500 mg71 (1)
Febrile syndrome3×500 mg71 (1)
without focus 1 (1)4×500 mg71 (1)
  • *Median (range).